Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen

Pediatr Blood Cancer. 2007 Nov;49(6):852-4. doi: 10.1002/pbc.20750.

Abstract

We report a case of a 6-month-old girl suffering from a kaposiform hemangioendothelioma of the chest wall, associated with Kasabach-Merritt phenomenon. Despite rapid intervention with cortisone and interferon alpha the tumor led to a life-threatening clinical condition with progressive growth and consumption coagulopathy under therapy. Because therapy for kaposiform hemangioendotheliomas with a single anti-angiogenic or anti-proliferative agent has not been reported to be very successful, we administered vincristine, combined with cyclophosphamide, actinomycin D, and methotrexate in a critically ill patient. After six cycles of the applied four-drug regiment, the infant was in remission, which has been maintained for 5 months since stopping therapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cortisone / administration & dosage
  • Critical Illness
  • Cyclophosphamide / administration & dosage
  • Dactinomycin / administration & dosage
  • Female
  • Hemangioendothelioma / drug therapy*
  • Hemangioendothelioma / pathology
  • Humans
  • Infant
  • Interferon-alpha / administration & dosage
  • Methotrexate / administration & dosage
  • Remission Induction
  • Thoracic Neoplasms / drug therapy*
  • Thoracic Neoplasms / pathology
  • Vincristine / administration & dosage

Substances

  • Interferon-alpha
  • Dactinomycin
  • Vincristine
  • Cyclophosphamide
  • Cortisone
  • Methotrexate